By: Benzinga
Downside Protection For Regeneron Pharmaceuticals
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN ) closed up 4.2% on Thursday, to $288.83, after climbing over $294 intraday. The company had announced on Tuesday that it would release clinical trial data for its Macular Edema treatment EYLEA at the annual meeting of the American Academy of Ophthalmology
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here